Fluorescent Affibody Peptide Penetration in Glioma Margin Is Superior to Full Antibody

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Sexton, Kristian ^a   Tichauer, Kenneth ^a   Samkoe, Kimberley S ^b   Gunn, Jason ^a   Hoopes, P Jack ^a,b   Pogue, Brian W ^a,b  

^a DARTMOUTH COLLEGE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR AFFIBODY; FLUORESCENT DYE; GREEN FLUORESCENT PROTEIN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; AUTOFLUORESCENCE IMAGING; BRAIN SLICE; CANCER DIAGNOSIS; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG TUMOR LEVEL; EX VIVO STUDY; FEMALE; GLIOMA; HUMAN; HUMAN CELL; MOUSE; NEUROIMAGING; NONHUMAN; PLASMA CLEARANCE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; FEMALE; FLUORESCENCE; GLIOMA; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; MICE, NUDE; PEPTIDES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS;

MUS;

EID: 84876071085     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060390     Document Type: Article

References (53)

1. Toda M, (2008) Intraoperative navigation and fluorescence imagings in malignant glioma surgery. Keio J Med 57: 155-161.
2. Roberts DW, Valdes PA, Harris BT, Fontaine KM, Hartov A, et al. (2011) Coregistered fluorescence-enhanced tumor resection of malignant glioma: relationships between delta-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. Clinical article. J Neurosurg 114: 595-603.
3. Devaux BC, O'Fallon JR, Kelly PJ, (1993) Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 78: 767-775.
4. Valdes PA, Kim A, Leblond F, Conde OM, Harris BT, et al. (2011) Combined fluorescence and reflectance spectroscopy for in vivo quantification of cancer biomarkers in low- and high-grade glioma surgery. J Biomed Opt 16: 116007.
5. Valdes PA, Leblond F, Jacobs VL, Wilson BC, Paulsen KD, et al. (2012) Quantitative, spectrally-resolved intraoperative fluorescence imaging. Sci Rep 2: 798.
6. Valdes PA, Leblond F, Kim A, Harris BT, Wilson BC, et al. (2011) Quantitative fluorescence in intracranial tumor: implications for ALA-induced PpIX as an intraoperative biomarker. J Neurosurg 115: 11-17.
7. Nitta T, Sato K, (1995) Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas. Cancer 75: 2727-2731.
8. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, et al. (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7: 392-401.
9. Stummer W, Reulen HJ, Novotny A, Stepp H, Tonn JC (2003) Fluorescence-guided resections of malignant gliomas-an overview. Acta Neurochir Suppl 88: 9-12.
10. Moore GE, Peyton WT, et al. (1948) The clinical use of fluorescein in neurosurgery; the localization of brain tumors. J Neurosurg 5: 392-398.
11. Shinoda J, Yano H, Yoshimura S, Okumura A, Kaku Y, et al. (2003) Fluorescence-guided resection of glioblastoma multiforme by using high-dose fluorescein sodium. Technical note. J Neurosurg 99: 597-603.
12. Hefti M, Mehdorn HM, Albert I, Dorner L, (2010) Fluorescence-Guided Surgery for Malignant Glioma: A Review on Aminolevulinic Acid Induced Protoporphyrin IX Photodynamic Diagnostic in Brain Tumors. Current Medical Imaging Reviews 6: 254-258.
13. Bottomley SS, Muller-Eberhard U, (1988) Pathophysiology of heme synthesis. Semin Hematol 25: 282-302.
14. el-Sharabasy MM, el-Waseef AM, Hafez MM, Salim SA, (1992) Porphyrin metabolism in some malignant diseases. Br J Cancer 65: 409-412.
15. Stummer W, Stocker S, Novotny A, Heimann A, Sauer O, et al. (1998) In vitro and in vivo porphyrin accumulation by C6 glioma cells after exposure to 5-aminolevulinic acid. J Photochem Photobiol B 45: 160-169.
16. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, et al. (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62: 564-576; discussion 564-576.
17. Valdes PA, Samkoe K, O'Hara JA, Roberts DW, Paulsen KD, et al. (2010) Deferoxamine iron chelation increases delta-aminolevulinic acid induced protoporphyrin IX in xenograft glioma model. Photochem Photobiol 86: 471-475.
18. Sanai N, Snyder LA, Honea NJ, Coons SW, Eschbacher JM, et al. (2011) Intraoperative confocal microscopy in the visualization of 5-aminolevulinic acid fluorescence in low-grade gliomas. J Neurosurg 115: 740-748.
19. Hansen DA, Spence AM, Carski T, Berger MS, (1993) Indocyanine green (ICG) staining and demarcation of tumor margins in a rat glioma model. Surg Neurol 40: 451-456.
20. Stewart PA, Hayakawa K, Farrell CL, Del Maestro RF, (1987) Quantitative study of microvessel ultrastructure in human peritumoral brain tissue. Evidence for a blood-brain barrier defect. J Neurosurg 67: 697-705.
21. Lampson LA, (2011) Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier. mAbs 3: 153-160.
22. Gerstner ER, Fine RL, (2007) Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: Establishing a treatment paradigm. Journal of Clinical Oncology 25: 2306-2312.
23. Utsuki S, Oka H, Sato S, Shimizu S, Suzuki S, et al. (2007) Histological examination of false positive tissue resection using 5-aminolevulinic acid-induced fluorescence guidance. Neurol Med Chir (Tokyo) 47: 210-213; discussion 213-214.
24. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, et al. (1987) Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A 84: 6899-6903.
25. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, et al. (1985) Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313: 144-147.
26. Schnell O, Krebs B, Wagner E, Romagna A, Beer AJ, et al. (2008) Expression of integrin alpha(v)beta(3) in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathology 18: 378-386.
27. Gibbs-Strauss SL, Samkoe KS, O'Hara JA, Davis SC, Hoopes PJ, et al. (2010) Detecting epidermal growth factor receptor tumor activity in vivo during cetuximab therapy of murine gliomas. Academic radiology 17: 7-17.
28. Gibbs-Strauss S (2008) Noninvasive fluorescence monitoring for functional assessment of murine glioma treatment [Thesis]. ProQuest/UMI: Dartmouth College. 281 p.
29. Rosen GD, Williams AG, Capra JA, Connolly MT, Cruz B, et al. (2000) The Mouse Brain Library. Available: www.mbl.org. Accessed 2013 March 7: Int Mouse Genome Conference.
30. Gibbs-Strauss SL, O'Hara JA, Srinivasan S, Hoopes PJ, Hasan T, et al. (2009) Diagnostic detection of diffuse glioma tumors in vivo with molecular fluorescent probe-based transmission spectroscopy. Medical Physics 36: 974-983.
31. Samkoe KS, Gibbs-Strauss SL, Yang HH, Hekmatyar SK, Hoopes PJ, et al. (2011) Image contrast in fluorescence and magnetic resonance images for glioblastoma detection. 78920O-78920O-78925.
32. Gibbs-Strauss SL, Samkoe KS, O'Hara JA, Davis SC, Hoopes PJ, et al. (2010) Detecting epidermal growth factor receptor tumor activity in vivo during cetuximab therapy of murine gliomas. Acad Radiol 17: 7-17.
33. Samkoe KS, Sexton K, Tichauer KM, Hextrum SK, Pardesi O, et al. (2011) High Vascular Delivery of EGF, but Low Receptor Binding Rate Is Observed in AsPC-1 Tumors as Compared to Normal Pancreas. Mol Imaging Biol.
34. Samkoe KS, Sexton K, Tichauer K, Davis SC, O'Hara JA, et al. (2011) Determination of blood plasma fluorescence extinction coefficients for dyes used in three-compartment binding model. 78860A-78860A-78865.
35. Nigrovic V, (1993) Plasma drug concentrations: description and interpretation of the biexponential decay. Br J Anaesth 71: 908-914.
36. Tofts PS, Kermode AG, (1991) Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 17: 357-367.
37. McCabe KE, Wu AM, (2010) Positive progress in immunoPET-not just a coincidence. Cancer Biother Radiopharm 25: 253-261.
38. Lofblom J, Feldwisch J, Tolmachev V, Carlsson J, Stahl S, et al. (2010) Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 584: 2670-2680.
39. Holliger P, Hudson PJ, (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23: 1126-1136.
40. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J, (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1: 1311-1318.
41. Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA, Mueller BM, (1993) Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother 37: 343-349.
42. Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G, (2008) The biological properties of cetuximab. Crit Rev Oncol Hematol 68: 93-106.
43. Tolmachev V, Friedman M, Sandstrom M, Eriksson TL, Rosik D, et al. (2009) Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J Nucl Med 50: 274-283.
44. Friedman M, Orlova A, Johansson E, Eriksson TL, Hoiden-Guthenberg I, et al. (2008) Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J Mol Biol 376: 1388-1402.
45. Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, et al. (1996) Comparison of methods for analysis of clinical [11C]raclopride studies. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism 16: 42-52.
46. Nordberg E, Friedman M, Gostring L, Adams GP, Brismar H, et al. (2007) Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. Nucl Med Biol 34: 609-618.
47. Stummer W, Novotny A, Stepp H, Goetz C, Bise K, et al. (2000) Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 93: 1003-1013.
48. Nicholson C, (2001) Diffusion and related transport mechanisms in brain tissue. Reports on Progress in Physics 64: 815-884.
49. Thorne RG, Hrabetova S, Nicholson C, (2004) Diffusion of epidermal growth factor in rat brain extracellular space measured by integrative optical imaging. J Neurophysiol 92: 3471-3481.
50. Klein P, Mattoon D, Lemmon MA, Schlessinger J, (2004) A structure-based model for ligand binding and dimerization of EGF receptors. Proc Natl Acad Sci U S A 101: 929-934.
51. Kim ES, Khuri FR, Herbst RS, (2001) Epidermal growth factor receptor biology (IMC-C225). Current Opinion in Oncology 13: 506-513.
52. Ennis BW, Lippman ME, Dickson RB, (1991) The EGF receptor system as a target for antitumor therapy. Cancer Invest 9: 553-562.
53. Binz HK, Amstutz P, Pluckthun A, (2005) Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 23: 1257-1268.